跳至主要内容
临床试验/ISRCTN88417663
ISRCTN88417663终止未知

Impact of CYP2C9 genotype and CYP2C9 inhibiting drugs on an individual’s metabolomics and metabolism of tolbutamide for interrogation of drug interactions

niversity of Dundee0 个研究点目标入组 6 人开始时间: 2021年5月21日最近更新:
适应症

试验速览

阶段
未知
状态
终止
发起方
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Aged 18 - 60 years
  • 2. Caucasian (to limit genetic variation as much as possible)
  • 3. Not known to have diabetes
  • 4. No daily treatment with antidiabetic medication, statins, amitriptyline or other drugs that inhibit or require CYP2C9 or CYP3A4 metabolism
  • 5. No cognitive impairment or visual impairment
  • 6. Known CYP2C9 genotype – either normal (wild type”) or two reduced function alleles

排除标准

  • 1. Heterozygous CYP2C9 genotype i.e. only one reduced function allele
  • 2. Use of any antifungal drug within the last month
  • 3. Recent involvement (<30 days) in a clinical trial
  • 4. Pregnancy or planning to conceive
  • 5. Inability/unwillingness to comply with the protocol
  • 6. Anaemia

研究者

发起方
niversity of Dundee

相似试验